3 results
The purpose of this clinical trial is to test whether treatment of patients with NSCLC with erlotinib plus sunitinib is better than treatment with erlotinib plus placebo. All patients enrolling in this study will receive treatment with erlotinib.
Primary• To assess the efficacy of a fixed dose of pregabalin to placebo during the first12-week treatment period in subjects with RLS.• To compare the rate of augmentation of a fixed dose of pregabalin to 2 fixed doses ofpramipexole over 9 or 12…
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…